Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAT | P04040 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xeruborbactam SCHEMBL23655292 | 0.88 | CAT (1.00) | CAT | |
| Xeruborbactam SCHEMBL22854594 | 0.88 | CAT (1.00) | CAT | |
| Xeruborbactam SCHEMBL21012432 | 0.88 | CAT (1.00) | CAT | |
| Xeruborbactam SCHEMBL21012430 | 0.88 | CAT (1.00) | CAT | |
| Xeruborbactam SCHEMBL21012607 | 0.88 | CAT (1.00) | CAT | |
| SCHEMBL22821240 | 0.77 | CAT (0.64) | CAT | |
| SCHEMBL22821243 | 0.77 | CAT (0.60) | CAT | |
| SCHEMBL25739040 | 0.76 | CAT (0.74) | CAT | |
| SCHEMBL25739018 | 0.76 | CAT (0.78) | CAT | |
| SCHEMBL21012603 | 0.75 | CAT (0.64) | CAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4201942-A1 | BORACIC ACID COMPOUND | Phaeno Therapeutics Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-20230144152-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2020257306-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144152-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BTD, BLK, BCL6B | CAT 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.